No Data
No Data
Goldman Sachs Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $9
Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday
Goldman Sachs Upgrades Adaptive Biotechnologies(ADPT.US) to Buy Rating, Raises Target Price to $9
Goldman Sachs Upgrades Adaptive Biotechnologies to Buy From Neutral, Adjusts Price Target to $9 From $8
Adaptive Biotechnologies (ADPT): Among Stocks Insiders Are Selling In March
BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $10